Divi’s Laboratories (DIVISLAB) investor relations material

Executive summary

• Q1 FY 2027 saw resilient business performance with consolidated total income reaching INR 3,144 crores, up from INR 2,529 crores year-over-year, and strong execution in custom synthesis and generics.

• Profit before tax rose to INR 1,180 crores from INR 733 crores; profit after tax increased to INR 902 crores from INR 545 crores year-over-year.

• Standalone total income was INR 3,037 crores, with profit after tax at INR 891 crores for the quarter.

• Strategic focus on backward integration, capacity expansion, and technology advancement supported operational reliability and supply assurance.

• CSR initiatives impacted over 1.8 million beneficiaries in Andhra Pradesh and Telangana during 2026.

Financial highlights

• Standalone revenue from operations for Q1 FY 2027 was INR 2,974 crores, up from INR 2,357 crores year-over-year.

• Standalone profit before tax was INR 1,165 crores, up from INR 747 crores year-over-year.

• Standalone earnings per share (EPS) for the quarter was INR 33.55, compared to INR 20.95 in Q1 last year; consolidated EPS was INR 33.95, up from INR 20.49.

• Custom synthesis contributed 60% and generics 40% to the revenue mix.

• Global nutraceutical business revenue was INR 298 crores, up from INR 250 crores year-over-year.

Outlook and guidance

• Management reiterated expectations for double-digit revenue growth for the full year, with lumpiness possible due to regulatory approval timelines and product mix.

• Gross and EBITDA margins are expected to be comparable or slightly better than last year, but quarterly fluctuations are anticipated.

• Continued focus on expanding peptide capacity and advancing multiple projects through validation and commercialization stages.

• Board approved the unaudited financial results for the quarter ended June 30, 2026.